Welcome to the Copenhagen Trial Unit − The CTU

The CTU is a clinical intervention research unit conducting clinical research within all specialties. We offer flexible collaboration and consulting at all stages of clinical research.

The CTU has been involved in the conduct of more than 162 randomised clinical trials in which more than 135,000 participants were randomised. We provide expertise and infrastructure in planning, conduct, analysis, and interpretation of randomised clinical trials, including development of trial methodology and education.

The CTU has been involved in the conduct of more than 500 protocols for systematic reviews, which has materialised in the publication of more than 300 systematic reviews published within and outside The Cochrane Collaboration. The CTU has developed methodology and software for conducting Trial Sequential Analysis (TSA). We provide advice, support, and full collaboration during the protocol and systematic review development. We offer expertise in search strategy design, conduct literature searches for systematic reviews, and offer help with or conduct of meta-analyses.

The CTU hosts the Editorial Team Office of the Cochrane Hepato-Biliary Group (CHBG) – one of the 56 global Collaborative Review Groups within The Cochrane Collaboration – as well as the Danish Clinical Research Infrastructures Network (DCRIN) and the Danish coordinating hub of the Nordic Trial Alliance (NTA).

Since the establishment in 1995, the CTU has produced an average of 38 publications per year. By December 2023, the CTU had a Hirsch index of 100.

We offer creative collaboration and consulting from concept, through conduct and to completion.

News

Wichmann S, Barbateskovic M, Liang N, et al. Loop diuretics in adult intensive care patients with fluid overload: a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis. An Intensive Care. 2022 Jun 13;12(1):52. doi: 10.1186/s13613-022-01024-6. PMID: 35696008 Free PMC article. Review.
View here
Barakji J, Korang SK, Feinberg J, et al. Cannabinoids versus placebo for pain: A systematic review with meta-analysis and Trial Sequential Analysis. PLoS ONE 18(1): e0267420. 2023 Jan 30 doi: https://doi.org/10.1371/journal.pone.0267420
View here
Riberholt CG, Olsen MH, Milan JB, et al. Major mistakes and errors in the use of Trial Sequential Analysis in systematic reviews or meta-analyses - protocol for a systematic review. Syst Rev. 2022 Jun 4;11(1):114. doi: 10.1186/s13643-022-01987-4. PMID: 35659769 Free PMC article.
View here
Pereira Ribeiro J, Lunde C, Gluud C, et al. Methylphenidate denied access to the WHO List of Essential Medicines for the second time. BMJ Evid Based Med. BMJ Evid Based Med. Resusc Plus. 2022 Jun 2;10:100258. doi: 10.1016/j.resplu.2022.100258. eCollection 2022 Jun. PMID: 35677835 Free PMC article.
View here
Jørgensen CK, Olsen MH, Nielsen N, et al. Centre for Statistical and Methodological Excellence (CESAME): A Consortium Initiative for Improving Methodology in Randomised Clinical Trials. Health Services Insights. 2023;16. doi:10.1177/11786329231166519
View here
Petersen JJ, Jørgensen CK, Faltermeier P, et al. Drug interventions for prevention of COVID-19 progression to severe disease in outpatients: a systematic review with meta-analyses and trial sequential analyses (The LIVING Project). BMJ Open 2023;13:e064498. doi:10.1136/ bmjopen-2022-064498
View here
Hansen ML, Pellicer A, Hyttel‑Sørensen S, et al. Cerebral Oximetry Monitoring in Extremely Preterm Infants. N Engl J Med 2023;388:1501-11. DOI: 10.1056/NEJMoa2207554
View here
Rijal A, Nielsen EE, Adhikari TB, et al. Effects of adding exercise to usual care in patients with either hypertension, type 2 diabetes or cardiovascular disease: a systematic review with meta-analysis and trial sequential analysis. Br J Sports Med 2023;57:930–939 doi:10.1136/bjsports-2022-106002.
View here
Rasmussen MI, Hansen ML., Pellicer A, et al. Cerebral oximetry monitoring versus usual care for extremely preterm infants: a study protocol for the 2-year follow-up of the SafeBoosC-III randomised clinical trial. Trials 24, 653 (2023). https://doi.org/10.1186/s13063-023-07653-x
View here
Skrifvars MB, Ameloot K, Grand J, et al. Protocol for an individual patient data meta-analysis on blood pressure targets after cardiac arrest. Acta Anaesthesiol Scand. 2022 May 26. doi: 10.1111/aas.14090.
View here
Nørskov AK, Jakobsen JC, Afshari A,et al. Collaboration for Evidence-based Practice and Researchin Anaesthesia (CEPRA): A consortium initiative forperioperative research.Acta Anaesthesiol Scand. 2023;67(6):804‐810. doi:10.1111/aas.1423
View here
Niemela V, Siddiqui F, Ameloot K, et al.Higher versus lower blood pressure targets after cardiac arrest: Systematic review with individual patient data meta-analysis. 2023 june. DOI:https://doi.org/10.1016/j.resuscitation.2023.109862
View here
Olsen MH, Hansen ML, Lange T, et al. Detailed statistical analysis plan for a secondary Bayesian analysis of the SafeBoosC-III trial: a multinational, randomised clinical trial assessing treatment guided by cerebral oximetry monitoring versus usual care in extremely preterm infants. Trials 24, 737 (2023). https://doi.org/10.1186/s13063-023-07720-3
View here
Wichmann S, Lange T, Perner A, et al. Furosemide versus placebo for fluid overload in intensive carepatients—The randomised GODIF trial second version:Statistical analysis plan. Acta Anaesthesiol Scand. 2023;1‐7.doi:10.1111/aas.14320
View here